| Name | (2E,4E)-5-(7-methoxy-3,3-dimethyl-2H-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid |
|---|---|
| Synonyms |
Oxeglitazar
UNII-LKX634SL5X |
| Description | Oxeglitazar is an orally active compound that can be used for the research of type II diabetes[1]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.154g/cm3 |
|---|---|
| Boiling Point | 491.7ºC at 760mmHg |
| Molecular Formula | C19H22O4 |
| Molecular Weight | 314.37600 |
| Flash Point | 174.4ºC |
| Exact Mass | 314.15200 |
| PSA | 55.76000 |
| LogP | 4.08430 |
| Vapour Pressure | 1.75E-10mmHg at 25°C |
| Index of Refraction | 1.586 |
|
~85%
280585-34-4 |
| Literature: Merck Patent GmbH Patent: WO2004/31166 A1, 2004 ; Location in patent: Page 10 ; |